Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma.
10.3348/kjr.2015.16.1.125
- Author:
Yi Sheng LIU
1
;
Ming Ching OU
;
Yi Shan TSAI
;
Xi Zhang LIN
;
Chien Kuo WANG
;
Hong Ming TSAI
;
Ming Tsung CHUANG
Author Information
1. Department of Diagnostic Radiology, National Cheng-Kung University Hospital, Tainan 704, Taiwan, R.O.C. taicheng100704@yahoo.com.tw
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Chemoembolization;
Drug-eluting bead;
Hepatocellular carcinoma;
Doxorubicin;
Microsphere
- MeSH:
Abdominal Pain/etiology;
Adult;
Aged;
Antibiotics, Antineoplastic/*administration & dosage/adverse effects;
Carcinoma, Hepatocellular/*drug therapy/mortality;
Chemoembolization, Therapeutic;
Disease-Free Survival;
Doxorubicin/*administration & dosage/adverse effects;
Drug Carriers/*chemistry;
Ethiodized Oil/chemistry;
Female;
Fever/etiology;
Follow-Up Studies;
Gelatin/chemistry;
Humans;
Kaplan-Meier Estimate;
Liver Neoplasms/*drug therapy/mortality;
Male;
Microspheres;
Middle Aged;
Retrospective Studies
- From:Korean Journal of Radiology
2015;16(1):125-132
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB). MATERIALS AND METHODS: A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5%) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9%) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5%) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated. RESULTS: No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1% vs. 6.3% or 2.4%). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0% vs. 57.8% or 68.3%). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7%, 34.1%, and 5.7%, respectively. CONCLUSION: In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.
